Press Releases
Chicago, July 7, 2015 - The international Serious Adverse Events Consortium (iSAEC) announces completion of its program to standardize SAE phenotype definitions.
Chicago, January 20, 2015 - The international Serious Adverse Events Consortium (iSAEC) announces data release from its global research collaboration to identify genetic markers related to drug induced serious adverse events.
Chicago, September 16, 2014 - The international Serious Adverse Events Consortium announces research result Clozapine-induced agranulocytosis is associated with rare HLA-B and HLA-DQB1 alleles.
Chicago, September 14, 2014 - The international Serious Adverse Events Consortium announces PRED4 study result -- HLA DQA1-DRB1 variants predispose to pancreatitis induced by the thiopurine immunosuppressants.
Chicago, August 08, 2013 - The international Serious Adverse Events Consortium announces PRED4 study to research the role genetics plays in drug induced serious events associated with inflammatory bowel disease treatment.
Chicago, August 07, 2013 - The international Serious Adverse Events Consortium announces completion of clinical enrollment into its drug induced liver injury (DILI) and hypersensitivity/skin rash (ITCH) genomics cohorts.
Chicago, January 11, 2013 - The International Serious Adverse Event Consortium launches a new international consortium (DIRECT) to research the role genetics plays in drug induced renal injury.
Chicago, August 21, 2012 - The International Serious Adverse Event Consortium and UC San Diego to collaborate on research into the genetics of drug induced renal injury.
Chicago, March 20, 2012 - International Serious Adverse Events Consortium (iSAEC) announces sixth data release from its global research collaboration to identify genetic markers related to drug induced serious adverse events.
Chicago, November 17, 2011 - Consortium of Finnish universities to partner with the international Serious Adverse Events Consortium to research the genetics of drug induced liver injury and skin injury using electronic health records.
Chicago, November 2, 2011 - International Serious Adverse Events Consortium (iSAEC) announces its fourth data release from its global research collaboration to identify genetic markers related to drug induced serious adverse events.
Chicago, June 22, 2011 - iSAEC and Catholic Health Initiatives Center for Translational Research Collaberate to find Genetic Markers of Drug-Induced Serious Adverse Events.
Chicago, June 15, 2011 - Shanghai Jiao Tong University to partner with the International Serious Adverse Events Consortium to research the genetics of drug induced serious adverse events.
Chicago, May 4, 2011 - McGill University to partner with the International Dili Consortium to research the genetics of drug induced liver injury associated with tuberculosis therapy.
Chicago, February 2, 2011 - The International Serious Adverse Events Consortium (iSAEC) and the HMO Research Network (HMORN) collaborate to use electronic medical records to research genetics of drug-induced SAEs.
Chicago, January 30, 2011 - The International Serious Adverse Events Consortium (iSAEC) announces publication of whole genome study of drug induced serious skin rash.
Chicago, September 30, 2010 - Unique public/private partnership expands research to identify predictive genetic markers for drug-induced serious adverse events.
Chicago, September 30, 2010 - The International Serious Adverse Events Consortium (iSAEC) announces its fourth data release from its Global Research Collaboration to identify genetic markers related to drug induced serious adverse events.
Chicago, September, 2010 - The University of Liverpool and the International Serious Adverse Event Consortium to Partner on the development and execution of the International Hypersensitivity Consortium to research into the genetics of drug Induced hypersensitivity reactions.
Chicago, September, 2010 - Newcastle University and The International Serious Adverse Event Consortium to partner on the development and execution of the International DILI Consortium to research into the genetics of drug induced liver injury.
Chicago, June 17, 2010 - Broad Institute and the International Serious Adverse Event Consortium to partner on research into the genetics of augmentin induced liver injury.
Chicago, May 5, 2010 - Cerner Corporation and the International Serious Adverse Events Consortium to collaborate on studies to research the genetics of drug induced serious adverse events.
Chicago, January 27, 2010 - Duke University’s Center for Human Genome Variation and The International Serious Adverse Event Consortium to partner on research into the genetics of Clozapine induced Agranulocytosis.
Chicago, December, 2009 - The International Serious Adverse Events Consortium (iSAEC) announces its third data release relating to its global research collaboration to identify genetic markers related to drug induced serious adverse events.
Chicago, November, 2009 - PGxHealth, division of Clinical Data, Inc., contributes its Clozapine patient samples to the International Serious Adverse Event Consortium.
Chicago, October 21, 2009 – The International Serious Adverse Events Consortium and the HMO Research Network (HMORN) form research partnership to study how electronic medical records can address genetics of drug safety.
Chicago, May 31, 2009 – FDA and International Consortium Report New Data on Drug-Induced Liver Injury.
Chicago, April 8, 2009 – Academic Collaborator Partners With The International Serious Adverse Events Consortium (iSAEC) To Conduct Genomic Research On Drug Induced Cardiac Arrhythmia.
Chicago, February 9, 2009 – Press Release - FDA and International Serious Adverse Events Consortium Release First Data on Genetic Basis of Adverse Drug Events.
Chicago, June 25, 2008 – Press Release - Two academic collaborators join international Serious Adverse Events Consortium.
Chicago, May 29, 2008 – Press Release - Four leading companies join the international Serious Adverse Events Consortium.
Chicago, September 27, 2007 – Press Release - Official launch of the Serious Adverse Events Consortium.
News
September 9th, 2008 - Cerner collaborates with the International SAE Consortium to Study Drug-related Serious Adverse Events
Presentations
- iSAEC Research Update, FDA meeting (May 2013)
- Idiosyncratic DILI: It’s in the Genome, "Why DILI Idiosyncrasy? The Immune System and Beyond” meeting (March 2012)
- iSEAC Overview & Update, Shanghai Jiaotong University (February 2012)
- iSAEC Collaborative Overview, Cerner Health Conference (October 2011)
- iSAEC Update & Perspective, UK Pharmacogenetics & Stratified Medicines Meeting, UK (September 2011)
- iSAEC Update & Perspective, 1st ISTM Meeting, Beijing, China (May 2011)
- iSAEC Overview & Update, London Genetics PGx Conference, Windsor, UK (November 2010)
- iSAEC Overview, Results, and Future Directions. Cerner Healthcare Conference, (October 2010)
- Statistical and Genomic Challenges for Clinical Studies and Practice, University of Washington (October 2010)
- The Wellcome Trust Meeting on Pre-Competitive Boundaries and Open Innovation in Drug Discovery and Development (June 2010)
- Presentation by Matt Nelson (GSK, co-chair of the iSAEC Scientific Management Committee) at the HMORN-iSEAC Project Review Meeting (June 2010)
- American Association for the Study of Liver Disease Meeting (2010)
- Introductory comments
- Results presentation
- The Sentinel Initiative Annual Public Workshop (January 2010)
- Japanese PGx Data Science Consortium Symposium (October 2009)
- The Welcome Trust/CSHL bi-annual Pharmacogenetics Meeting (September 2009)
- MHC II Haplotype Marker for Lumiracoxib Injury, Timothy M. Wright, MD, Novartis, Recent Research Advances in Drug-Induced Liver Injury (April 2009)